CEPI and Institut Pasteur de Dakar announce 10-year partnership to boost manufacturing of affordable vaccines for the Global South

Partnership will advance equitable access to vaccines by expanding IPD's capacity to produce routine immunization vaccines across multiple technologies, and reserve capacity to rapidly supply vaccines to Global South countries during disease outbreaks. Collaboration will see CEPI invest up to $50 million over 10 years. IPD joins CEPI's global manufacturing network which will support agile and resilient manufacturing in the Global South - boosting and accelerating access to life-saving vaccines during future outbreaks and pandemics. 19 January 2023; OSLO, Norway and DAKAR, Sénégal: The Coalition for Epidemic Preparedness Innovations (CEPI) and the Institut Pasteur de Dakar (IPD) today announced a partnership that will advance equitable access to vaccines in Africa and contribute to the African Union's goal of increasing African manufacturers' share of vaccine supply to the continent to 60% by 2040. The collaboration will boost the manufacturing of affordable vaccines at IPD's facilities in Dakar, and reserve capacity to produce vaccines specifically for Global South countries during future outbreaks and pandemics to combat the kind of inequity that characterised the response to COVID-19. CEPI is creating a new network of vaccine manufacturers in Global South countries to substantially increase the world's capacity and capability to produce vaccines against emerging outbreaks and pandemic threats. IPD becomes part of this network, having manufactured WHO prequalified yellow fever vaccines for 80 years, and with the ambition to become a regional manufacturing hub making vaccines in Africa, for Africa, through Project MADIBA[1]. IPD will initially receive up to US$15 million in grant funding over three years, with the option to extend the partnership's scope and funding to a total of up to US$50 million over 10 years. CEPI's investment will complement that of other major funders for MADIBA, including the European Union, European Investment Bank, the Agence Française de Développement, the Islamic Development Bank, the International Finance Corporation, the U.S. International Development Finance Corporation, the Government of Germany and the Government of Sénégal. The first phase of the partnership will support the development and sustainability of IPD's manufacturing facilities for routine and outbreak vaccinations across multiple vaccine technologies and prepare them to begin supplying vaccines to Global South countries within 100 days of a new pathogen being identified. This timing is key to stopping future emerging disease outbreaks from becoming pandemics. Known as the 100 Days Mission, the goal is supported by the leaders of the G7 and G20 and industry executives and is at the heart of CEPI's plan to end pandemics. The partnership will enhance and equip the Drug Substance manufacturing capability at IPD to produce outbreak vaccines, launch a bioprocessing laboratory to accelerate vaccine production and reduce costs, invest in specialist workforce training and development, and support the development of IPD's quality management system. [1] Project MADIBA - Manufacturing in Africa for Disease Immunization and Building Autonomy